A bill filed in Maine would legalize psilocybin mushroom therapy without a medical diagnosis, and allow adults 21-and-older to legally buy the psychedelic and use... Bill to Legalize Psilocybin Therapy Introduced in Maine

A bill filed in Maine would legalize psilocybin mushroom therapy without a medical diagnosis, and allow adults 21-and-older to legally buy the psychedelic and use it under the supervision of a certified psilocybin service practitioner, according to the Dales Report.

The measure would include a 15% tax on retail sales of psilocybin products and allow manufacturing in a vertically-integrated model. The measure directs the state Department of Health and Human Services to establish guidelines for psilocybin treatment, such as personal possession restrictions, product testing, and standards for psilocybin care providers.

The bill says that those recommendations should be designed “to otherwise make this Act as consistent as possible in substance to the laws governing psilocybin in Oregon,” the report says. During the November 2020 election, Oregon voters approved a measure to legalize psilocybin therapy and Washington, D.C. voters moved to decriminalize all psychedelic plants, representing a watershed moment for psychedelic drug reforms.
Read More

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )